SCHEMBL2260441

SCHEMBL2260441

CCOC(=O)Cc1cnc2ccc(CC)cn12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.47
GAA P10253 4/20 0.47
GLA P06280 3/20 0.47
TGFBR1 P36897 1/20 0.40
CYP4Z1 Q86W10 1/20 0.39
ALDH1A1 P00352 2/20 0.38
HPGD P15428 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
HSD17B10 Q99714 2/20 0.38
TBXAS1 P24557 1/20 0.38
NPC1 O15118 1/20 0.38
TP53 P04637 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP2C19 P33261 1/20 0.38
RAB9A P51151 1/20 0.38
SLC2A2 P11168 1/20 0.37
RXFP1 Q9HBX9 2/20 0.37
MAPT P10636 1/20 0.37
TRPM8 Q7Z2W7 1/20 0.36
IDO1 P14902 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3595383 0.88 POLB (0.46) KDM4EGAAGLATGFBR1CYP4Z1
SCHEMBL2263014 0.84 KDM4E (0.46) KDM4EGAAGLATGFBR1ALDH1A1
SCHEMBL3604567 0.83 TGFBR1 (0.43) KDM4EGAAGLATGFBR1CYP4Z1
SCHEMBL2262019 0.82 KDM4E (0.39) KDM4EGAAGLATGFBR1RXFP1
SCHEMBL2265835 0.82 TGFBR1 (0.43) KDM4EGAAGLATGFBR1CYP4Z1
SCHEMBL3595719 0.81 KDM4E (0.42) KDM4EGAAGLATGFBR1ALDH1A1
SCHEMBL2261118 0.78 MAPK1 (0.49) KDM4EGAAGLAALDH1A1HPGD
SCHEMBL10038837 0.76 SLC2A2 (0.49) KDM4EGAACYP4Z1SMN1; SMN2NPC1
SCHEMBL20985982 0.73 KDM4E (0.45) KDM4EGAAGLAALDH1A1HPGD
SCHEMBL20986107 0.73 KDM4E (0.45) KDM4EGAAGLAALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110294792-A1 PURINE DERIVATIVES AS KINASE INHIBITORS ELI LILLY AND COMPANY (US) 2011-12-01 US disclosed
US-8058425-B2 Purine derivatives as kinase inhibitors ELI LILLY AND COMPANY (US) 2011-11-15 US disclosed
US-8022065-B2 Purine derivatives as kinase inhibitors ELI LILLY AND COMPANY (US) 2011-09-20 US disclosed
US-20110207721-A1 PURINE DERIVATIVES AS KINASE INHIBITORS ELI LILLY AND COMPANY (US) 2011-08-25 US disclosed
US-20090105229-A1 PURINE DERIVATIVES AS KINASE INHIBITORS ELI LILLY AND COMPANY 2009-04-23 US disclosed
US-7491716-B2 Purine derivatives as kinase inhibitors ELI LILLY AND COMPANY (US) 2009-02-17 US disclosed
EP-1483265-B1 PURINE DERIVATIVES AS KINASE INHIBITORS LILLY CO ELI (US) 2006-11-22 EP disclosed
US-20050090483-A1 Purine derivatives as kinase inhibitors ELI LILLY AND COMPANY 2005-04-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050090483-A1 Purine derivatives as kinase inhibitors PNP, ADK, NME2 KDM4E 1308/4885GAA 2654/4885GLA 4475/4885
US-20110294792-A1 PURINE DERIVATIVES AS KINASE INHIBITORS PNP, ADK, NME2 KDM4E 1308/4885GAA 2654/4885GLA 4475/4885
US-20110207721-A1 PURINE DERIVATIVES AS KINASE INHIBITORS PNP, ADK, NME2 KDM4E 1308/4885GAA 2654/4885GLA 4475/4885
US-20090105229-A1 PURINE DERIVATIVES AS KINASE INHIBITORS PNP, ADK, NME2 KDM4E 1308/4885GAA 2654/4885GLA 4475/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.